Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / AMGN

Stock rating · Biological Products, (No Diagnostic Substances)

Amgen Inc (AMGN) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Amgen Inc 62 out of 100 (Runner!). Its highest factor score is earnings track record at 87, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

AMGN · composite score

62/100
Runner!
Nov 20
Rating date
Live price in the app →
Quality73
Momentum68
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About Amgen Inc

Amgen is a biotechnology company developing human therapeutics. Its main products include the red blood cell boosters Epogen and Aranesp, the immune boosters Neupogen and Neulasta, Enbrel and Otezla for inflammatory diseases, the bone drugs Prolia/Xgeva (approved 2010) and Evenity (2019), and its first cancer therapy Vectibix (introduced 2006). The Onyx Pharmaceuticals acquisition added the oncology drug Kyprolis.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why AMGN scores 62/100

AMGN's 8 factor scores run from 36 to 87, and 4 of them sit above its composite of 62. Here is how AMGN breaks down.

Valuation42/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 17.3x, earnings growth accelerating
Business quality73/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 71%
  • ROE 78%
Price momentum68/100

Direction and relative strength of the recent share-price trend.

  • 50-day MA above 200-day (golden cross zone)
Earnings track record87/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +9%
Analyst sentiment55/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How AMGN compares

As of November 20, 2026, Amgen Inc ranks 4th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

Also ranked in Healthcare Stocks. All stock rating pages.

Key risks for AMGN

  • High debt-to-equity ratio 3.8x, rate-sensitive balance sheet
  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Amgen Inc sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds AMGN's momentum and catalyst factors above.

AMGN trade plan (Pro)

MELANY has a full position plan for Amgen Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates AMGN

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Amgen Inc's 62/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about AMGN

Is Amgen Inc (AMGN) a buy?

As of 2026-11-20, MELANY rated Amgen Inc Runner! with a composite score of 62/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does AMGN rank against similar companies?

As of November 20, 2026, Amgen Inc ranks 4th of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).

Should I buy Amgen Inc stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Amgen Inc (AMGN) Runner! with a composite of 62/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the AMGN stock price forecast?

MELANY does not publish price targets or forecasts for AMGN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 62/100 across eight factors for Amgen Inc, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for AMGN as of 2026-11-20: its analyst sentiment factor is 55/100, and its price momentum factor is 68/100.

Is AMGN stock overvalued or undervalued?

MELANY's valuation factor currently reads 42/100 for Amgen Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives AMGN's read.

What price should I buy AMGN at?

Rather than chasing the current price, MELANY computes a smart entry zone for AMGN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying AMGN stock?

The top risks MELANY currently flags for Amgen Inc: High debt-to-equity ratio 3.8x, rate-sensitive balance sheet; Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Amgen Inc a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 73/100 for Amgen Inc, and earnings track record, at 87/100. The 62/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will AMGN stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 68/100 for AMGN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this AMGN rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores AMGN as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, AMGN included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.